HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor–mutated non–small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy Journal Article
| Authors: | Yu, H. A.; Goto, Y.; Hayashi, H.; Felip, E.; Yang, J. C. H.; Reck, M.; Yoh, K.; Lee, S. H.; Paz-Ares, L.; Besse, B.; Bironzo, P.; Kim, D. W.; Johnson, M. L.; Wu, Y. L.; John, T.; Kao, S.; Kozuki, T.; Massarelli, E.; Patel, J.; Smit, E.; Reckamp, K. L.; Dong, Q.; Shrestha, P.; Fan, P. D.; Patel, P.; Sporchia, A.; Sternberg, D. W.; Sellami, D.; Jänne, P. A. |
| Article Title: | HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor–mutated non–small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 35 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-12-01 |
| Start Page: | 5363 |
| End Page: | 5375 |
| Language: | English |
| DOI: | 10.1200/jco.23.01476 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PMCID: | PMC10713116 |
| PUBMED: | 37689979 |
| DOI/URL: | |
| Notes: | Accession Number: 174033417 -- Entry Date: In Process -- Revision Date: 20231208 -- Publication Type: Journal Article -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8309333. -- Source: Cinahl |
